1. Apoptosis
  2. RIP kinase


Cat. No.: HY-18937 Purity: 98.56%
Handling Instructions

WEHI-345 is a potent and selective inhibitor of RIPK2, with IC50 of 0.13 μM.

For research use only. We do not sell to patients.
WEHI-345 Chemical Structure

WEHI-345 Chemical Structure

CAS No. : 1354825-58-3

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 132 In-stock
5 mg USD 120 In-stock
10 mg USD 190 In-stock
50 mg USD 660 In-stock
100 mg USD 990 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

    WEHI-345 purchased from MCE. Usage Cited in: Mol Cell. 2018 Feb 15;69(4):551-565.e7.

    THP1 cells are treated with muramyl dipeptide (MDP) for 30 min in the presence or absence of indicated kinase inhibitors (1 mM; added 1 hr prior) followed by lysis in 6 M urea buffer. Lysates are immunoprecipitated with K63 and linear ubiquitin chain antibodies, and precipitates and lysates are examined by western blotting using indicated antibodies.

    WEHI-345 purchased from MCE. Usage Cited in: J Immunol. 2017 May 1;198(9):3729-3736.

    Confocal images of lysozyme and procryptdin in cultured WT crypt organoids treated with GSK583 (5 μM) or mock-treated (A), or WEHI-345 (2.5 μM) or mock-treated (B) for 16 hours.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References


    WEHI-345 is a potent and selective inhibitor of RIPK2, with IC50 of 0.13 μM. IC50 value: 0.13 μM Target: RIPK2 in vitro: WEHI-345 is a selective RIPK2 kinase inhibitor, which delays RIPK2 ubiquitylation and NF-κB activation downstream of NOD engagement. WEHI-345 is an ATP analogue and was therefore predicted to bind in the ATP-binding pocket of RIPK2. WEHI-345 proved to be highly specific for RIPK2(Kd=46 nM) and displayed negligible activity (>10 μM) against RIPK1, RIPK4 and RIPK5. in vivo: WEHI-345 inhibits NOD signalling and has a beneficial effect on an EAE model. WEHI-345 blocks MDP-induced cytokine production. WEHI-345 ameliorates experimental autoimmune encephalomyelitis in mice. WEHI-345 also potently inhibited MDP-induced cytokine and chemokine secretion in the mouse macrophage Raw 264.7 cell line.

    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 2.4909 mL 12.4545 mL 24.9091 mL
    5 mM 0.4982 mL 2.4909 mL 4.9818 mL
    10 mM 0.2491 mL 1.2455 mL 2.4909 mL
    Please refer to the solubility information to select the appropriate solvent.
    Molecular Weight




    CAS No.




    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: ≥ 32 mg/mL

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name



    Applicant name *


    Email address *

    Phone number *


    Organization name *

    Country *


    Requested quantity *


    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cat. No.: